These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3164 related articles for article (PubMed ID: 27114329)
1. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection. Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329 [TBL] [Abstract][Full Text] [Related]
2. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist. Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046 [TBL] [Abstract][Full Text] [Related]
3. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Zhu X; Ye H; Fu Y Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446 [TBL] [Abstract][Full Text] [Related]
4. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928 [TBL] [Abstract][Full Text] [Related]
5. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975 [TBL] [Abstract][Full Text] [Related]
6. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Kuang Y; Hong Q; Chen Q; Lyu Q; Ai A; Fu Y; Shoham Z Fertil Steril; 2014 Jan; 101(1):105-11. PubMed ID: 24161646 [TBL] [Abstract][Full Text] [Related]
7. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207 [TBL] [Abstract][Full Text] [Related]
8. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study. Wei LH; Ma WH; Tang N; Wei JH Taiwan J Obstet Gynecol; 2016 Feb; 55(1):50-4. PubMed ID: 26927248 [TBL] [Abstract][Full Text] [Related]
9. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study. Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834 [TBL] [Abstract][Full Text] [Related]
10. Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles. Chen H; Wang Y; Lyu Q; Ai A; Fu Y; Tian H; Cai R; Hong Q; Chen Q; Shoham Z; Kuang Y Fertil Steril; 2015 May; 103(5):1194-1201.e2. PubMed ID: 25813280 [TBL] [Abstract][Full Text] [Related]
11. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Zhu X; Ye H; Fu Y Fertil Steril; 2017 Sep; 108(3):505-512.e2. PubMed ID: 28697910 [TBL] [Abstract][Full Text] [Related]
12. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Kuang Y; Chen Q; Fu Y; Wang Y; Hong Q; Lyu Q; Ai A; Shoham Z Fertil Steril; 2015 Jul; 104(1):62-70.e3. PubMed ID: 25956370 [TBL] [Abstract][Full Text] [Related]
13. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates. Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671 [TBL] [Abstract][Full Text] [Related]
14. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. Dong J; Wang Y; Chai WR; Hong QQ; Wang NL; Sun LH; Long H; Wang L; Tian H; Lyu QF; Lu XF; Chen QJ; Kuang YP BJOG; 2017 Jun; 124(7):1048-1055. PubMed ID: 28276192 [TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial. Wang Y; Kuang Y; Chen Q; Cai R Trials; 2018 Aug; 19(1):455. PubMed ID: 30134964 [TBL] [Abstract][Full Text] [Related]
16. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial. Yıldız GA; Şükür YE; Ateş C; Aytaç R Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659 [TBL] [Abstract][Full Text] [Related]
17. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization. Jiang S; Kuang Y Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429 [TBL] [Abstract][Full Text] [Related]
19. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept. Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069 [TBL] [Abstract][Full Text] [Related]
20. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles. Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]